ProMetic Life Sciences Inc. (PFSCF.PK, PLI.TO) announced that it has received a $4.8 million purchase order under its ongoing supply agreement with Octapharma, Swiss based, independent global plasma fractionation company that specializes in human proteins. Total shipments to Octapharma are expected to significantly increase in 2013 over 2012.
The company said that the latest order relates to the purchase of PrioClear, a proprietary prion capture resin incorporated into Octapharma's manufacturing process for its solvent/detergent treated plasma product, Octaplas. Octaplas is currently approved for marketing in USA and several European countries.
For comments and feedback: editorial@rttnews.com